---

---

entities : Astrazeneca plc   

save search

---

Cellectis Announces Strategic Collaboration and Investment Agreements with AstraZeneca
Published: 2023-11-01 (Crawled : 07:00) - globenewswire.com
CLLS | News | $2.64 17K |

Health Technology

| 172.16% | O: 179.38% H: 10.33% C: -2.58%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 10.91% | O: 0.03% H: 1.17% C: 0.84%
collaboration

---

Genprex Announces First Patient Dosed in Phase 2a Expansion of Acclaim-1 Clinical Study of Reqorsa® Therapy in Combination with Tagrisso® to Treat Non-Small Cell Lung Cancer
Published: 2024-02-05 (Crawled : 12:30) - prnewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 5.18% | O: -0.17% H: 0.09% C: -2.76%
GNPX | $2.163 830 |

Health Technology

| -63.45% | O: 33.84% H: 1.01% C: -15.3%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 6.84% | O: -0.76% H: 0.77% C: 0.0%
reqorsa first lung cancer treat cell expansion therapy study

---

Genprex Receives U.S. FDA Fast Track Designation for REQORSA™ Immunogene Therapy in Combination With Keytruda® for the Treatment of Non-Small Cell Lung Cancer
Published: 2022-01-03 (Crawled : 15:00) - biospace.com/
AZNCF | News | $138.73 3.7K |

Health Technology

| 19.75% | O: 2.49% H: 1.06% C: -2.49%
GNPX | $2.163 830 |

Health Technology

| 64.89% | O: 16.79% H: 0.0% C: 0.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 20.39% | O: 0.03% H: 0.17% C: 0.07%
keytruda fast track designation treatment fda fast track gene therapy cel fda fast track lung cancer therapy cancer designation

---

F-star Therapeutics Enters into Exclusive Licensing Agreement with AstraZeneca for Novel STING Inhibitors
Published: 2021-07-08 (Crawled : 14:15) - biospace.com/
FSTX | $7.12 0.0% 0 |

Health Technology

| -3.07% | O: 14.31% H: 0.24% C: -4.53%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 17.35% | O: -0.52% H: 0.37% C: -0.32%
license

---

NeoGenomics Appoints Lynn Tetrault Interim CEO
Published: 2022-05-16 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.73 3.7K |

Health Technology

| 10.26% | O: 1.73% H: 0.86% C: -1.11%
NEO | $13.75 2.46% 22K |

Health Services

| 59.57% | O: 13.56% H: 1.47% C: -6.7%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 12.17% | O: 1.52% H: 0.0% C: 0.0%
ceo

---

Avenue Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
Published: 2022-11-10 (Crawled : 00:00) - biospace.com/
AZNCF | News | $138.73 3.7K |

Health Technology

| 15.13% | O: 6.22% H: 3.13% C: -0.56%
FBIO | $1.8 2.86% 25K |

Health Technology

| 127.66% | O: 0.17% H: 6.48% C: -1.81%
ATXI | $0.1301 35K |

Health Technology

| -93.09% | O: -10.64% H: 30.29% C: 25.6%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 14.87% | O: 7.08% H: 0.84% C: -0.43%
therapeutics financial results

---

Diabetes Drugs Global Market Report 2022: Featuring AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck, Pfizer & More
Published: 2023-03-22 (Crawled : 00:00) - prnewswire.com
GLAXF | News | $20.305 630 |

Health Technology

| 15.05% | O: 1.11% H: 0.0% C: 0.0%
SNYNF | News | $92.7 600K |

Health Technology

| -5.09% | O: 5.54% H: 0.96% C: 0.96%
AZNCF | News | $138.73 3.7K |

Health Technology

| 2.34% | O: -1.81% H: 0.51% C: 0.51%
JNJ | News | $148.88 -0.16% 940K |

Health Technology

| -1.28% | O: 0.08% H: 0.34% C: -0.03%
GSK | News | $40.795 0.51% 150K |

Health Technology

| 16.3% | O: 1.69% H: 0.11% C: -0.76%
LLY | News | $735.9 0.63% 180K |

Health Technology

| 120.97% | O: -0.02% H: 1.34% C: 0.53%
SNY | News | $47.36 0.45% 120K |

Health Technology

| -5.21% | O: 6.53% H: 0.56% C: -0.54%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 5.35% | O: 1.56% H: 0.34% C: -0.52%
report global diabetes market

---

Clostridium Diagnostics Market to grow at a CAGR of 13.69% from 2022 to 2027, Driven by the growing prevalence of CDI - Technavio
Published: 2023-03-27 (Crawled : 11:00) - prnewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 1.49% | O: 0.55% H: 1.46% C: -0.08%
TMO | News | $567.7 3.52% 540K |

Health Technology

| -1.77% | O: 0.99% H: 0.78% C: -0.37%
NVS | News | $98.17 3.21% 780K |

Health Technology

| 13.37% | O: 6.51% H: 1.75% C: 1.4%
TRIB | $1.81 110 |

Health Technology

| 93.58% | O: 1.6% H: 0.0% C: -6.32%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 3.27% | O: 1.46% H: 0.53% C: -0.25%
growing diagnostics market

---

HUTCHMED Reports 2021 Interim Results and Provides Business Updates
Published: 2021-07-28 (Crawled : 12:00) - globenewswire.com
LLY | News | $735.9 0.63% 180K |

Health Technology

| 200.24% | O: -0.09% H: 2.07% C: 1.29%
HCM | $17.98 6.14% 16K |

Health Technology

| -53.53% | O: 6.45% H: 7.99% C: 7.76%
BGNE | $137.95 5.35% 14K |

Health Technology

| -51.37% | O: 3.23% H: 13.33% C: 12.51%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 22.05% | O: -0.75% H: 0.7% C: -0.39%
results

---

Akoya Biosciences to Host Inaugural Spatial Day on December 15, 2021
Published: 2021-11-22 (Crawled : 13:30) - globenewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 23.21% | O: 1.53% H: 0.0% C: -0.1%
AKYA | News | $4.0 2.56% 4.5K |

Professional, Scientific, and T...

| -68.01% | O: 6.15% H: 2.32% C: 1.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 22.41% | O: -1.17% H: 0.0% C: 0.0%
bioscience

---

Artelo Biosciences Reports Fiscal 2021 Year-End Financial Results and Provides Business Update
Published: 2021-11-29 (Crawled : 17:00) - globenewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 23.47% | O: -0.0% H: 0.0% C: 0.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 23.95% | O: -1.57% H: 0.0% C: 0.0%
ARTL | News | $1.3004 13K |

Health Technology

| 82.87% | O: 5.5% H: 0.0% C: -11.8%
financial results bioscience results

---

Avalo Therapeutics Transfers Anti-IL-18 Antibody, AVTX-007 (camoteskimab) to Apollo Therapeutics
Published: 2022-08-01 (Crawled : 23:00) - biospace.com/
AZNCF | News | $138.73 3.7K |

Health Technology

| 6.13% | O: 2.39% H: 0.0% C: -0.9%
AVTX | $13.09 7.21% 12K |

Manufacturing

| 239.17% | O: 4.72% H: 10.08% C: -4.51%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 5.89% | O: 0.44% H: 0.53% C: -1.31%
il-18 therapeutics

---

Breast Cancer Therapeutics Market 2023, USD 15.64 billion Growth is Expected between 2023 to 2028, Robust pipeline and new drug approvals to Boost Growth - Technavio
Published: 2024-01-30 (Crawled : 18:00) - prnewswire.com
GLAXF | News | $20.305 630 |

Health Technology

| 5.21% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $138.73 3.7K |

Health Technology

| 5.7% | O: 3.41% H: 0.0% C: -2.45%
VTRS | News A | $11.3 0.44% 570K |

Health Technology

| -4.74% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $98.17 3.21% 780K |

Health Technology

| -12.05% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $40.795 0.51% 150K |

Health Technology

| 3.84% | O: 4.04% H: 1.57% C: -3.02%
ABBV | News | $169.22 0.79% 370K |

Health Technology

| 1.8% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $47.36 0.45% 120K |

Health Technology

| -7.95% | O: 1.75% H: 0.0% C: 0.0%
PBYI | $5.225 1.06% 10K |

Health Technology

| 8.5% | O: -0.1% H: 2.31% C: -1.26%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 4.36% | O: 0.82% H: 0.12% C: -1.64%
AMGN | News | $273.97 0.76% 69K |

Health Technology

| -13.58% | O: 0.44% H: 0.2% C: -0.55%
drug breast expected cancer pipeline therapeutics growth market

---

Topical Corticosteroids Market to Grow by USD 1.08 billion between 2022 to 2027, globally at 4% CAGR - Technavio
Published: 2024-01-30 (Crawled : 23:00) - prnewswire.com
ALPMF | News | $9.75 6.33% 0 |

Health Technology

| -15.58% | O: 4.34% H: 0.0% C: 0.0%
GLAXF | News | $20.305 630 |

Health Technology

| 5.21% | O: 5.68% H: 0.77% C: 0.77%
AZNCF | News | $138.73 3.7K |

Health Technology

| 5.7% | O: 3.41% H: 0.0% C: -2.45%
ALPMY | News | $9.53 690K |

Manufacturing

| -17.63% | O: 0.0% H: 1.38% C: 0.26%
VTRS | News A | $11.3 0.44% 570K |

Health Technology

| -4.74% | O: -0.08% H: 3.47% C: -0.25%
NVS | News | $98.17 3.21% 780K |

Health Technology

| -12.05% | O: -2.04% H: 0.19% C: -1.97%
GSK | News | $40.795 0.51% 150K |

Health Technology

| 3.84% | O: 4.04% H: 1.57% C: -3.02%
ABBV | News | $169.22 0.79% 370K |

Health Technology

| 1.8% | O: 0.5% H: 0.07% C: -0.81%
SNY | News | $47.36 0.45% 120K |

Health Technology

| -7.95% | O: 1.75% H: 0.0% C: 0.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 4.36% | O: 0.82% H: 0.12% C: -1.64%
market

---

Blueprint Medicines Reports First Quarter 2022 Results
Published: 2022-05-03 (Crawled : 12:00) - biospace.com/
BPMC | $92.03 1.57% 23K |

Health Technology

| 54.23% | O: 3.73% H: 5.92% C: 3.09%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 5.98% | O: 0.48% H: 1.18% C: 1.02%
results

---

Idiopathic Pulmonary Fibrosis Market to Reach $6.16 Bn, Globally, by 2030 at 7.0% CAGR: Allied Market Research
Published: 2022-02-07 (Crawled : 13:30) - prnewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 25.51% | O: 2.69% H: 0.5% C: -1.76%
BMY | $49.28 0.29% 800K |

Health Technology

| -22.06% | O: 3.7% H: 1.64% C: 1.24%
GLPG | News | $29.18 0.38% 6K |

Health Technology

| -55.31% | O: 2.54% H: 1.58% C: 0.1%
FGEN | $1.255 10.09% 220K |

Health Technology

| -92.23% | O: -1.09% H: 9.3% C: 8.82%
BIIB | $195.03 0.47% 32K |

Health Technology

| -9.82% | O: 2.54% H: 0.0% C: 0.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 24.63% | O: -0.14% H: 1.01% C: 0.87%
fibrosis research

---

Caelum and Alexion Present Additional Phase 2 Data Reinforcing Safety and Tolerability of CAEL-101 in AL Amyloidosis at the European Hematology Association Congress 2021
Published: 2021-06-11 (Crawled : 11:00) - biospace.com/
FBIO | $1.8 2.86% 25K |

Health Technology

| -59.3% | O: 3.49% H: 0.9% C: 0.9%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 19.19% | O: 0.49% H: 0.03% C: -0.61%
phase 2 europe als

---

FASENRA approved for treatment of children aged 6 to 11 with severe asthma
Published: 2024-04-11 (Crawled : 12:00) - biospace.com/
AZNCF | News | $138.73 3.7K |

Health Technology

| 1.82% | O: 1.47% H: 1.16% C: -1.27%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 3.71% | O: 3.34% H: 0.27% C: -0.62%
children approved treatment for

---

Psoriasis Treatment Market Players Observe Rising Trend of Personalized Medicines, According to TMR Report
Published: 2022-06-24 (Crawled : 12:00) - prnewswire.com
AZNCF | News | $138.73 3.7K |

Health Technology

| 9.49% | O: 0.64% H: 4.18% C: 1.33%
NVSEF | News | $95.11 5.4% 0 |

Health Technology

| 44.84% | O: 6.71% H: 0.0% C: -0.1%
PFE | News A | $26.375 0.44% 1.9M |

Health Technology

| -46.71% | O: 2.96% H: 0.0% C: 0.0%
NVS | News | $98.17 3.21% 780K |

Health Technology

| 16.16% | O: 2.38% H: 0.0% C: 0.0%
JNJ | News | $148.88 -0.16% 940K |

Health Technology

| -15.66% | O: 1.94% H: 0.0% C: 0.0%
LLY | News | $735.9 0.63% 180K |

Health Technology

| 136.58% | O: 3.32% H: 0.0% C: 0.0%
AZN | News | $70.48 0.5% 500K |

Health Technology

| 10.11% | O: 4.41% H: 0.0% C: 0.0%
treatment report psoriasis market

---

AstraZeneca progresses Ambition Zero Carbon programme with Honeywell partnership to develop next-generation respiratory inhalers
Published: 2022-02-22 (Crawled : 21:00) - biospace.com/
AZN | News | $70.48 0.5% 500K |

Health Technology

| 17.16% | O: 3.24% H: 0.18% C: -1.6%
partnership program respiratory one

---

Gainers vs Losers

84%

16%

Top 10 Gainers

MTTR | News M | $4.625 165.81% 5.5M |

AGBA | $2.46 96.8% 28M |

Finance

EDBL | News | $7.37 96.01% 650K |

CZOO | $7.74 55.11% 2.7M |

PALI | $7.64 54.97% 14M |

Manufacturing

OPRT | News | $3.19 41.78% 3M |

Finance

PEGY | $0.0629 37.34% 110M |

Manufacturing

ZAPP | $6.02 35.59% 95K |

n/a

MLEC | $1.87 33.57% 1.6M |

n/a

ATGL | $3.66 27.97% 150K |

---

Your saved searches

---